Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
NCT02314481Phase 2Completed
- Sponsor
- University College London
- Start
- May 2017
- Primary completion
- Nov 2025
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, vemurafenib, alectinib, trastuzumab emtansine in non-small cell lung cancer (NSCLC), sponsored by University College London. Started May 2017; status: completed.
02
Drugs
atezolizumabvemurafenibalectinibtrastuzumab emtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02314481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314481.